Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

BRAF and KRAS mutations in stomach cancer

Abstract

Ras proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. BRAF, which encodes a RAF family member in the downstream pathway of RAS, is somatically mutated in a number of human cancers. The activating mutation of BRAF is known to play a role in tumor development. As there have been no data on the BRAF mutation in stomach cancer, we analysed the genomic DNAs from 319 stomach carcinomas for the detection of somatic mutations of BRAF. Overall, we detected BRAF mutations in seven stomach carcinomas (2.2%). Five of the seven BRAF mutations involved Val 599, the previously identified hotspot, but the substituted amino acid (V599 M) was different from the most common BRAF mutation (V599E). The remaining two mutations involved a conserved amino acid (D593G). One tumor had both BRAF and KRAS mutations. This is the first report on BRAF mutation in stomach cancer, and the data indicate that BRAF is occasionally mutated in stomach cancer, and suggest that alterations of RAS pathway both by RAS and BRAF mutations contribute to the pathogenesis of stomach cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Arber N, Shapira I, Ratan J, Stern B, Hibshoosh H, Moshkowitz M, Gammon M, Fabian I and Halpern Z . (2000). Gastroenterology, 118, 1045–1050.

  • Bae JM, Won YJ, Jung KW, Suh KA, Ahn DH and Park JG . (1999). J. Korean Cancer Assoc., 30, 1175–1183.

  • Bos JL . (1989). Cancer Res., 49, 4682–4689.

  • Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR and Weber BL . (2002). Cancer Res., 62, 6997–7000.

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.

  • Jiang W, Kahn SM, Guillem JG, Lu SH and Weinstein IB . (1989). Oncogene, 4, 923–928.

  • Kolch W . (2000). Biochem. J., 351 (Part 2), 289–305.

  • Lee KH, Lee JS, Suh C, Kim SW, Kim SB, Lee JH, Lee MS, Park MY, Sun HS and Kim SH . (1995). Cancer, 75, 2794–2801.

  • Naoki K, Chen TH, Richards WG, Sugarbaker DJ and Meyerson M . (2002). Cancer Res., 62, 7001–7003.

  • Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D and Bloomfield CD . (1994). Blood, 83, 1603–1611.

  • Peyssonnaux C and Eychene A . (2001). Biol. Cell, 93, 53–62.

  • Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM and Meltzer PS . (2003). Nat. Genet., 33, 19–20.

  • Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE . (2002). Nature, 418, 934.

  • Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE and Herlyn M . (2003). Cancer Res., 63, 756–759.

  • Shin MS, Park WS, Kim SY, Kanf SJ, Song KY, Park JY, Dong SM, PiJH, Oh RR, Lee JY, Yoo NJ and Lee SH . (1999). Am. J. Pathol., 154, 1785–1791.

  • Smith ML, Snaddon J, Neat M, Cambal-Parrales M, Arch R, Lister TA and Fitzgibbon J . (2003). Leukemia, 17, 274–275.

  • Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY . (2002). Cancer Res., 62, 6451–6455.

Download references

Acknowledgements

This work was supported by Grant (No. R02-2002-000-00050-0) from the KOSEF.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nam Jin Yoo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, S., Lee, J., Soung, Y. et al. BRAF and KRAS mutations in stomach cancer. Oncogene 22, 6942–6945 (2003). https://doi.org/10.1038/sj.onc.1206749

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206749

Keywords

This article is cited by

Search

Quick links